CLL
61 programs · 60 companies
Programs
61
Companies
60
Trials
53
MOAs
39
SOS1iMALT1iPCSK9iALKiRAS(ON)iCDK2iPRMT5iMDM2iTYK2iAuroraAi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Phase 2 | AHR | ||
| NVS-3297 | Preclinical | CDK2 | ||
| MRK-8368 | Phase 3 | ALK | ||
| BMY-2495 | Phase 3 | KRASG12D | ||
| SNY-9073 | Phase 2 | B7-H3 | ||
| DSN-3066 | Phase 3 | IL-13 | ||
| AMG-4531 | Phase 2/3 | KRASG12C | ||
| GIL-2037 | Approved | KRASG12D | ||
| REG-647 | Preclinical | SMN2 | ||
| Olpainavolisib | Phase 1 | Menin | ||
| BGN-6990 | Phase 2/3 | BCMA | ||
| RVM-7089 | Phase 3 | IL-17A | ||
| MDG-4513 | Phase 1/2 | CD3 | ||
| CGO-9628 | Phase 2/3 | AuroraA | ||
| ETN-5063 | Phase 1/2 | USP1 | ||
| Kemanesiran | Approved | JAK1 | ||
| Gozeosocimab | Preclinical | B7-H3 | ||
| 451-5171 | Preclinical | KRASG12D | ||
| Tezesacituzumab | NDA/BLA | IL-23 | ||
| Nidatenlimab | NDA/BLA | KRASG12D | ||
| Sotoratamab | Phase 2 | GLP-1R | ||
| MD-IIT-841 | Phase 1 | KRASG12D | ||
| CER-4594 | Phase 3 | TROP-2 | ||
| HOR-3601 | Phase 1/2 | FXIa | ||
| Zorinesiran | Phase 2/3 | JAK2 | ||
| Darasacituzumab | Phase 1 | MALT1 | ||
| CN-8014 | Phase 2/3 | Aβ | ||
| Teravorutinib | Phase 1/2 | TYK2 | ||
| Lisoderotide | Phase 3 | SHP2 | ||
| Adagrazasiran | Approved | CD3 | ||
| MRN-6769 | Phase 2/3 | PD-1 | ||
| Tezesotorasib | Preclinical | SHP2 | ||
| Surasacituzumab | Phase 3 | AuroraA | ||
| MYO-1420 | Preclinical | Menin | ||
| Mavucagene | NDA/BLA | JAK2 | ||
| NVE-9059 | Approved | IL-23 | ||
| INS-9902 | Phase 1/2 | JAK2 | ||
| SCR-7300 | NDA/BLA | CGRP | ||
| Suratapinarof | NDA/BLA | PD-L1 | ||
| Datotuximab | Phase 1/2 | TROP-2 | ||
| 006-2012 | Phase 1/2 | BCL-2 | ||
| CUR-8000 | Phase 2 | Aβ | ||
| Mavuderotide | Preclinical | CGRP | ||
| 4D-4097 | Approved | Nectin-4 | ||
| Rimasacituzumab | Phase 3 | C5 | ||
| 417-6972 | Preclinical | PRMT5 | ||
| NEO-5036 | Phase 1/2 | HER2 | ||
| Liracagene | NDA/BLA | Menin | ||
| SLN-2895 | Preclinical | CD20 | ||
| Zorilucimab | Approved | PSMA | ||
| Elrasacituzumab | Phase 2/3 | EGFR | ||
| Gelicapivasertib | Preclinical | Menin | ||
| MAN-3628 | Phase 1 | FXIa | ||
| INS-860 | Phase 2 | EZH2 | ||
| ASA-IIT-476 | Phase 3 | CDK4/6 | ||
| Pemicagene | Approved | IL-13 | ||
| Lisoderotide | Phase 1/2 | FcRn | ||
| Fixacagene | NDA/BLA | FLT3 | ||
| THE-8498 | Preclinical | PCSK9 | ||
| Bemazanubrutinib | Preclinical | C5 | ||
| Cevivorutinib | Phase 2/3 | KIF18A |
Trials (53)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT03445151 | PFE-2901 | Phase 2 | Active |
| NCT08424182 | NVS-3297 | Preclinical | Completed |
| NCT03238586 | MRK-8368 | Phase 3 | Not yet recr... |
| NCT08336762 | MRK-8368 | Phase 3 | Terminated |
| NCT05671728 | DSN-3066 | Phase 3 | Not yet recr... |
| NCT04329444 | DSN-3066 | Phase 3 | Recruiting |
| NCT03951302 | AMG-4531 | Phase 2/3 | Recruiting |
| NCT03742985 | AMG-4531 | Phase 2/3 | Active |
| NCT06869190 | GIL-2037 | Approved | Completed |
| NCT07607014 | GIL-2037 | Approved | Completed |
| NCT03694462 | Olpainavolisib | Phase 1 | Active |
| NCT06562395 | BGN-6990 | Phase 2/3 | Recruiting |
| NCT03123563 | RVM-7089 | Phase 3 | Terminated |
| NCT07785058 | MDG-4513 | Phase 1/2 | Active |
| NCT06721105 | ETN-5063 | Phase 1/2 | Recruiting |
| NCT03544093 | Kemanesiran | Approved | Recruiting |
| NCT04277055 | Kemanesiran | Approved | Terminated |
| NCT04058000 | Gozeosocimab | Preclinical | Active |
| NCT08278559 | Tezesacituzumab | NDA/BLA | Recruiting |
| NCT05501301 | Sotoratamab | Phase 2 | Terminated |